You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Selected published results of SRS (2000–2015) for the treatment of nonfunctioning pituitary adenomas

From: Target delineation and optimal radiosurgical dose for pituitary tumors

Authors Patients Type dose Follow-up Tumor Late toxicity (%)
of SRS (Gy) (months) control (%) visual hypopituitarism
Feigl et al., 2002 [33] 61 GK 15a 55.2 94 NA 40
Sheehan et al., 2002 [58] 42 GK 16a 31.2 97.6 2.4 0
Wowra & Stummer, 2002 [59] 30 GK 16a 55 93.3 (93 at 5 years) 0 10
Petrovich et al., 2003 [60] 56 GK 15a 36 100 3 4
Losa et al., 2004 [61] 52 GK 16.6a 41 96.3 (88.2 at 5 years) 0 9.3
Muacevic et al., 2004 [62] 51 GK 16.5a 21.7 95 0 3.9
Picozzi et al., 2005 [63] 51 GK 16.5a 40.6 96.1 NA NA
Iwai et al., 2005 [64] 34 GK 12.3a 59.8 87.1 (93 at 5 years) 0 6.5
Mingione et al., 2006 [65] 100 GK 18.5a 44.9 92.2 0 19.7
Voges et al., 2006 [66] 37 LINAC 13.4 56.6 100 1.4 12.3
Liscak et al., 2007 [67] 140 GK 20a 60 100 0 2
Pollock et al., 2008 [68] 62 GK 16a 64 96.8 (95 at 5 years) 0 27
Kobayashi et al., 2009 [69] 71 GK 14.1a 50.2 96.7 2.8 8.2
Hayashi et al., 2010 [70] 43 GK 18.2a 36 100 0 0
Gopalan et al., 2011 [71] 48 GK 18.4a 95 83.3 0 39
Iwata et al., 2011 [44] 100 CK 3×7/5×5 33 98 1 3
Park et al., 2011 [72] 125 GK 13a 62 90 (94 at 5 years) 0,8 24
Starke et al., 2012 [73] 140 GK 18a 50 89.6 (97 at 5 years) 0 30.3
Runge et al., 2012 [74] 61 LINAC 13 83 98 0 9.8
Wilson et al., 2012 [75] 51 LINAC 14 50 100 0 0
Sheehan et al., 2013 [76] 512 GK 16a 36 93.4 (95 at 5 years) 7.9 21
Lee et al., 2014 [77] 41 GK 12a 48 92.7 (85 at 10 years) 2.4 24.4
Bir et al., 2015 [78] 57 GK 15a 45.5 93 (90 % at 10 years) 0 8.8
  1. SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
  2. amarginal dose